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1 Introduction 
Alzheimer’s disease (AD) is a devastating neurodegenerative disorder of the elderly 
characterized by progressive cognitive impairment. The disease represents the most common 
cause of dementia, and the rising prevalence of the disease in aging populations poses 
significant challenges to societies around the globe. The situation is further complicated by 
the fact that clinicians still lack effective treatment options that could interfere with disease 
progression (Blennow et al. 2006).  The incidence of the disease has been described as 
strongly age-dependent: while almost negligible until the age of 60 years, and still below 1% 
in people aged 60-64 years, the incidence of AD has been reported to show an almost 
exponential increase with every 5 years after the age of 65 years (Ferri et al. 2005). The world-
wide prevalence was estimated at 46.8 million in 2015 and is expected to increase substantially 
in the future (Prince 2015). While rare single-gene mutations could be identified in cases of 
familial AD (FAD) that exhibit an autosomal-dominant inheritance and an earlier onset in 
life, the majority of cases, classified as sporadic AD (SAD), is believed to occur 
spontaneously. However, several genetic and acquired risk factors for SAD have been 
described. Notably positive family history of SAD has been found to significantly increase 
the risk of developing the disease (van Duijn et al. 1991). The Apolipoprotein E ε4 allele has 
been described as the most important independent genetic risk factor for SAD, which has 
been validated by studies on both the Framingham and the Rotterdam study cohorts (Corder 
et al. 1993; Myers et al. 1996; Slooter et al. 2004). Acquired risk factors that have been 
associated with SAD include vascular disease, hypertension, and hyperlipidemia as well as 
obesity and physical inactivity. Managing these modifiable risk factors is believed to bear 
great potential for the primary prevention of SAD (Norton et al. 2014).  
Pathological examination of a patient with AD reveals severe brain atrophy that is 
accompanied histologically by two characteristic hallmarks of the disease: extracellular 
neuritic plaques (NPs) composed of Amyloid-β (Aβ) and intracellular neurofibrillary tangles 
that are composed of hyperphosphorylated tau protein. NPs are found in the limbic as well 
as in the association cortices and axonal and dendritic injury of neurons is typically seen in 
proximity (Selkoe 2001). In the majority of AD cases concomitant cerebral amyloid 
angiopathy (CAA), i.e. deposition of Aβ to the vasculature and disruption of the vascular 
architecture, is observed (Biffi and Greenberg 2011).  
In principle, a definite diagnosis of the disease requires post-mortem histopathologic 
examination, which includes classification of neuropathology according to the Braak stage 
(Braak and Braak 1991). During lifetime though, careful clinical assessment of every patient 
with cognitive impairment allows determination of the most likely cause of the deficit in each 
individual case. Manifest AD typically shows a pattern of memory impairment that is 
distinctive from other forms of amnesic disorders and can be recognized by experienced 
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clinicians. In addition, neuropsychological testing, imaging of the CNS, and laboratory tests 
are applied to rule out other treatable causes of the deficit such as depression, 
hypothyroidism, or structural diseases of the brain (McKhann et al. 2011; Markowitsch and 
Staniloiu 2012). Evaluation of cerebrospinal fluid for biomarkers of neurodegeneration, 
typically Aβ42, total tau, and phospho-tau, may be carried out to increase diagnostic certainty 
in some cases, but is not routinely applied in the diagnostic procedure. The same holds true 
for the use of currently available methods of nuclear medicine, i.e. FDG-PET and HMPAO-
SPECT (Leitlinie Demenzen 2015). As sensitivity and specificity of the described diagnostic 
procedure is limited, especially in cases of AD with only mild cognitive impairment, possible 
biomarkers for a better diagnosis of incipient AD are being investigated. In the future more 
elaborate combinations of cerebrospinal-fluid (CSF) markers, as well as specific Aβ-specific 
imaging, may allow the identification of patients with incipient AD and even individuals at 
risk of developing the disease (Blennow et al. 2015).  
Highlighting the need for accurate diagnostic tools for the diagnosis of incipient AD, 
neuropathological changes have been found to begin long before obvious cognitive 
impairment (Villemagne et al. 2013). It is therefore believed that disease-modifying 
treatments would need to be started early in disease course, as neuropathological changes are 
assumed to be irreversible (Blennow et al. 2006). While disease-modifying treatments are 
under development, currently available and recommended drugs can only ameliorate 
symptoms of the disease. Drugs that are recommended for the use in AD include the 
Acetylcholine-Esterase-inhibitors Donezepil, Galantamin, and Rivastigmin and the NMDA 
antagonist Memantine. Considerations before initiation of a therapy include severity of the 
symptoms and possible side-effects of the respective drugs (Leitlinie Demenzen 2015).  
After Aβ peptides were isolated from the vasculature and NPs of AD brains and tangles were 
found to consist of hyperphosphorylated tau, questions arose about the role of Aβ and tau 
in pathogenesis of AD (Glenner and Wong 1984; Masters et al. 1985; Gorevic et al. 1986). 
The amyloid hypothesis was introduced in the early 1990s and proposed that the pivotal 
abnormality in AD-cases is an altered production of Aβ peptides that induces a cascade of 
pathologic events in which the accumulation of Aβ peptides precedes hyperphosphorylation 
of tau and formation of neurofibrillary tangles (Hardy and Allsop 1991; Hardy und Higgins 
1992).  
At first the concept of the amyloid hypothesis was essentially based on the recognition that 
the gene encoding the Amyloid-β precursor protein (APP) had been found to be located on 
chromosome 21 (Kang et al. 1987; Tanzi et al. 1987) and that individuals with trisomy 21 
(Down Syndrome; DS) were known to present AD-typical neuropathology at a young age 
(Olson and Shaw 1969). Further evidence for the hypothesis comes from studies on FAD 
cases, that were invariably found to be caused by single-gene mutations in genes implicated 
in the generation of Aβ peptides: the APP gene and the presenilin genes Presenilin 1 
(PSEN1) and Presenilin 2 (PSEN2) (Tanzi 2012). A continuing accrual of data suggests that 
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even subtle changes in Aβ production, especially an increase in the Aβ42:Aβ40 production 
rate, can facilitate pathogenesis of AD presumably through the formation of toxic oligomers 
(Haass and Selkoe 2007; Kuperstein et al. 2010).   
Although there is still lack of clarity in details, at present it is believed that an imbalance in 
production and clearance of Aβ peptides is essential for pathogenesis of AD. As reviewed 
by Hardy and Selkoe in recent years it is now justified to claim that the hypothesis is not only 
widely accepted, but that concerns with the concept, e.g. the observation that the number of 
amyloid plaques does not correlate well with cognitive decline, have been met with 
conclusive explanations and experiments. Furthermore the hypothesis has in fact laid the 
groundwork for promising therapeutic approaches (Hardy and Selkoe 2002; Selkoe and 
Hardy 2016).  
Aβ proteins are generated by processing of APP. In a first step the single-transmembrane 
protein APP is cleaved by the β-secretase enzyme. While the N-terminal ectodomain of APP 
is set free, the C-terminal fragment (β-CTF) remains membranebound. β-CTF undergoes 
further intramembranous proteolysis facilitated by γ-secretase, which releases a 37-43 amino 
acid Aβ protein (Haass et al. 2012). Notably the presenilin genes were found to encode for 
the active site of the γ-secretase (Strooper et al. 1998). This multiprotein complex has been 
described to determine the C-terminus of Aβ (Beher et al. 2002). The intramembranous 
proteolysis of β-CTF by γ-secretase is initiated by ε-cleavage, which occurs either at T48 or 
L49 of β-CTF (Funamoto et al. 2004). Further action of the γ-secretase ensues, with 
subsequent cleavage at every three to four amino acid residues. It has been speculated that 
two major product lines of Aβ emerge, in which the initial ε-cleavage would determine the 
outcome:  
Aβ49 > Aβ46 > Aβ43 > Aβ40 and Aβ48 > Aβ45 > Aβ42 > Aβ38 
This hypothesis has been established based on the detection of the corresponding tri- and 
tetrapeptides in vitro (Qi-Takahara et al. 2005; Takami et al. 2009). However, a recent study 
by Matsumura et al. found the two major product lines to be extensively interlinked by 
occasional γ-secretase cleavage at every fourth, fifth or sixth residue (Matsumura et al. 2014). 
This is in line with earlier studies on the generation of the C-terminally truncated Aβ peptide 
Aβ38, which found the peptide’s generation by γ-secretase to be independent from Aβ42 
generation (Czirr et al. 2008; Page et al. 2008). In addition, Aβ38 levels in CSF were found 
to correlate well with levels of Aβ40, while no correlation with Aβ42 levels could be 
established (Schoonenboom et al. 2005; Gabelle et al. 2010). Furthermore, the generation of 
the C-terminally truncated Aβ peptides Aβ37 and Aβ39 was demonstrated recently. Aβ39 
was found to result mainly from cleavage of Aβ42 as indicated by the detection of the GVV 
tripeptide. In contrast, Aβ37 was described to either result from cleavage of Aβ42, by release 
of the GVVIA pentapeptide or from cleavage of Aβ40 by release of the VIA tripeptide 
(Matsumura et al. 2014).  
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Interfering with the process of Aβ production by γ-secretase modulation has been suggested 
as a therapeutic strategy to reduce Aβ accumulation. Putative γ-secretase modulators (GSMs) 
should influence Aβ production in a way that lowers the production of toxic Aβ species like 
Aβ42. Importantly, other functions of the γ-secretase should not be compromised by a 
putative GSM (Czirr and Weggen 2006). The non-steroidal anti-inflammatory GSMs have 
been demonstrated to selectively decrease production of Aβ42. An effect that is achieved 
partially by increasing the levels of the C-terminally truncated Aβ species (Weggen et al. 2001; 
Beher et al. 2002).  
A recent study on a C-terminal fragment of Aβ, the hexapeptide Aβ32-37, underscores the 
importance of Aβ C-terminal truncations, as the fragment was found to be a potent peptide 
inhibitor of Aβ aggregation. In addition, Aβ toxicity in cell culture was mitigated by the 
hexapeptide (Bansal et al. 2016).  
Passive immunotherapy against Aβ is a promising therapeutic approach for AD and several 
antibodies targeting Abeta are currently being tested in clinical trials. It is worth noting that 
the antibodies that entered clinical trials target different epitopes of Aβ and show different 
binding properties, e.g. to monomeric or oligomeric forms of Aβ and to plaques (Selkoe and 
Hardy 2016). 
Depending on their C-terminus, Aβ peptides exhibit different propensities with longer Aβ 
species, being particularly prone to accumulation (Jarrett et al. 1993). Ever since the amyloid 
hypothesis has been put forward, research has focused on Aβ peptides, and studies on the 
deposition of the presumably most toxic variant Aβ42 and the most produced variant Aβ40 
are numerous. Aβ42 has been proposed to be the earliest peptide deposited within NPs and 
to represent the predominant species in parenchymal depositions of Aβ (Golde et al. 2000). 
In contrast Aβ40 has been found to be the most abundant species within the vasculature in 
cases of AD with concomitant CAA (Gravina et al. 1995). 
C-terminally truncated Aβ peptides however, have received little attention. Except for a  
recent study that focused on the deposition of Aβ38 in SAD and FAD cases (Moro et al. 
2012), depositions of C-terminally truncated Aβ peptides in AD have not been systematically 
studied. C-terminally truncated Aβ peptides have been consistently detected within the CSF 
(Wiltfang et al. 2002; Portelius et al. 2010a). Moreover they were found to be present in 
human plasma, although at low levels (Maler et al. 2007). It has been suggested that 
measurement of C-terminally truncated Aβ peptides would increase diagnostic accuracy of 
CSF sampling for the diagnosis of AD (Struyfs et al. 2015).  
The present study aims to investigate the deposition of C-terminally truncated Aβ peptides 
in AD. It extends earlier findings on Aβ38, which described the peptide to be mainly 
deposited to the vasculature (Tomidokoro et al. 2010; Moro et al. 2012), and for the first 
time it describes the predominant location and the severity of depositions of two further C-
terminally truncated Aβ peptides - Aβ37 and Aβ39 - in SAD in comparison with non-
demented control (NDC) cases. In addition, several cases of FAD, with underlying mutations 
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in the APP gene or the PSEN1 gene are analyzed. This includes analysis of the just recently 
described APP mutation I716F, which has not been investigated for deposition of Aβ 
peptides with different C-termini before (Guardia-Laguarta et al. 2010). The study further 
investigates a set of commonly used transgenic mouse models of AD for deposition of C-
terminally truncated Aβ peptides.  
This text summarizes and discusses the results of two publications. While publication I 
focusses on the depositions of Aβ38 in AD partly confirming and partly disputing earlier 
findings on the peptide, publication II for the first time analyzes the deposition of Aβ37 and 
Aβ39 in AD.  
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2 Patients, Materials and Methods 
2.1 Patients 
Brain tissue from patients with AD, patients with DS, and NDC cases was used in this study. 
Written informed consent about the use of their brain tissue for the purpose of research was 
obtained from each individual or their relatives. Brain tissue was provided by the following 
institutions: The Netherlands Brain Bank, Hôpital de la Salpêtrière Paris, University Hospital 
Helsinki, Uppsala Universitet, and Medizinische Universität Wien. 
In total, brain tissue from 13 cases of sporadic AD, 9 cases of NDC, 2 cases of AD with 
additionally diagnosed CAA (AD+CAA), and 3 cases of DS was investigated. In addition, 
brain tissue from several cases of FAD with underlying mutations in either the APP gene 
(figure 1) or the PSEN-1 gene was analyzed. The study included analysis of cases of the 
‘Swedish’ APP mutation KM670/671NL (Mullan et al. 1992), the ‘Arctic’ APP mutation 
E693G (Nilsberth et al. 2001), the APP mutation I716F (Sieczkowski et al. 2014), as well as 
the PSEN1 mutations P246L (Campion et al. 1995), L418F (Wirths et al. 2010), and cases of 
the PSEN1 mutation ΔExon 9 (Perez-tur et al. 1995). 
 
 
Figure 1: Diagram showing the primary protein sequence of the Aβ coding region within the 
longer APP and position of the three APP mutations that were analyzed for depositions of 
C-terminally truncated Aβ peptides in this study. Action of β-Secretase is indicated by a red 
arrow. Blue arrows indicate the subsequent cleavage by γ-Secretase that was proposed by Qi-
Takahara et al. as the underlying mechanism of the generation of Aβ peptides with varying 
C-termini (Qi-Takahara et al. 2005). Outlined arrows indicate the Aβ49 > Aβ46 > Aβ43 > 
Aβ40 product line, filled arrows indicate the Aβ48 > Aβ45 > Aβ42 > Aβ38 product line. 
Figure was made using Adobe Photoshop (Adobe Systems, San José, CA, USA).    
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Diagnosis was made according to established histopathological criteria. Classification 
according to Braak-stages, which is based on the severity of taupathology (Braak and Braak 
1991), was obtained for the analyzed SAD, AD+CAA, DS and NDC cases. 
2.2 Mouse Models 
For this study brain tissue from a set of established transgenic mouse models of AD was 
analyzed. These commonly used mouse models of the disease are known to show an AD-
like histopathology with varying degrees of NPs, taupathology and neuron loss. The analyzed 
models comprised PDAPP (Games et al. 1995), APP23 (Sturchler-Pierrat et al. 1997), 3xTg 
(Oddo et al. 2003), APP/PSEN1 Ex9 (Garcia-Alloza et al. 2006), 5xFAD (Oakley et al. 
2006), and APP/PSEN-KI (Casas et al. 2004).   
2.3 Antibodies  
The polyclonal affinity purified rabbit anti-Aβ38 antibody #218403 has been generated 
by Synaptic Systems (Göttingen) using a synthetic peptide LMVGG corresponding to the C-
terminus of Aβ38. Antibody specificity was demonstrated by an Enzyme-linked 
immunosorbent assay (ELISA) and a Dot-blot analysis, which were carried out by Henrik 
Martens of Synaptic Systems (refer to figure 1C of publication I). 
Table 1: Targets, names, suppliers, and types of antibodies used in different experiments. 
mAb = monoclonal antibody, pAb = polyclonal antibody, IP = Immunoprecipitation, IHC 
= Immunohistochemistry, IF = Immunofluorescence, WB = Western Blot; Epitope that 
was used for generation of the antibody in brackets (as stated by the respective supplier), 
1=Name of cell line, 2=Catalog number of supplier Synaptic Systems. 
Target (Epitope) Name Supplier Type Use Dilution in IHC  
Aβ (1-16) 6E101 Covance Mouse mAb IP n/a 
Aβ (17-2) 4G81 Covance Mouse mAb IHC 1:1000 
Aβ (N-Terminus) 1E81 Milipore Mouse mAb WB n/a 
Aβ 37 D2A6H1 Cell Signaling Rabbit mAb IHC, IF, WB 1:800 
Aβ 38 #2184032 Synaptic Systems Rabbit pAb IHC, IF 1:250 
Aβ 38 326 F11 Synaptic Systems Mouse mAb IHC, IF 1:250 
Aβ 38 BA1-131 Covance Rabbit mAb IHC 1:200 
Aβ 39 D5Y9L1 Cell Signaling Rabbit mAb IHC, IF, WB 1:400 
Aβ 40 G2101 Milipore Mouse mAb IHC, IF, WB 1:1000 
Aβ 42 #2187032 Synaptic Systems Rabbit pAb IHC 1:200 
 
To further confirm specificity of the antibody in an immunohistochemical (IHC) staining, 
an immunoadsorption protocol was carried out as previously described (Saul et al. 2013). In 
short, the anti-Aβ38 pAb #218403 was incubated with 1g Aβ4-38 overnight at 4°C under 
agitation. The supernatant that resulted from 5 min centrifugation at 14,000x g was used for 
2 Patients, Materials and Methods 10 
immunohistochemical stainings in a 6-month-old APP/PSEN1-KI mouse. At the same time 
an adjacent slice was stained using the antibody without prior immunoadsorption. 
2.4 Immunohistochemistry 
Paraffin-embedded brain tissue was sectioned into 4µm sagittal sections using a microtome. 
Sections were mounted onto slides, dried overnight at 37 °C and used for 3’3-
diaminobenzidine (DAB) immunohistochemistry (IHC). Sections were deparaffinized in a 
xylene bath and rehydrated using an ascending series of ethanol baths (70 %, 95 %, and 
100 %). To block activity of endogenous peroxidases, sections were incubated for 30 minutes 
in 0.3 % H2O2 in 0.01 M PBS. Antigen retrieval was achieved by two steps: At first sections 
were boiled in 0.01 M citrate puffer for 10 minutes using a microwave. In a second step, 
incubation in 88% formic acid was performed following permeabilization with 0.1 % Triton 
X-100 in 0.01 M PBS. Prior to incubation with primary antibodies, blockage of unspecific 
binding sites was ensured. Sections were circled with a lipid pen and a blockage solution 
consisting of 10 % fetal calf serum (FCS) and 4 % skim milk powder in 0.01 M PBS was 
applied. After incubation of the blockage solution for 1 hour at ambient temperature, the 
primary antibody diluted in 0.01 M PBS and 10 % FCS was applied to the sections and 
incubated overnight at ambient temperature. The respective dilution of primary antibodies 
used in IHC is specified in Table 1. After thorough washing steps, incubation with 
biotinylated secondary antibodies (DAKO, Glostrup 1:200) in 0.01 M PBS and 10 % FCS 
was performed at 37 °C for 1 hour, followed by washing steps and application of the ABC 
method with a Vectastain kit (Vector Laboratories, Burlingame, USA). The ABC solution 
was produced by adding both components of the kit to 0.01 M PBS containing 10 % FCS. 
Incubation was carried out at 37 °C for 1.5 hours. After washing steps, staining was revealed 
by short incubation with a solution containing the chromogen DAB (0.5 mg/ml DAB in 
50 mM Tris/HCl with 0.15 ‰ H2O2). Hematoxylin was used for counterstaining. Before 
application of mounting medium and cover slips, the slides were dehydrated using a 
descending series of ethanol baths (100 %, 95 %, 70 %) and xylene baths.  
With a camera-equipped microscope bright field images of the stained sections were 
acquired. Figures were generated using Adobe Photoshop (Adobe Systems, San José, CA, 
USA). Semiquantitative analysis of immunoreactivity in each section was performed for NPs 
and CAA. Aβ staining intensity was rated as follows: - absent staining; (+) scarce staining, + 
weak staining, ++ moderate staining, +++ abundant staining. 
2.5 Immunofluorescence 
Immunofluorescence (IF) staining was carried out to evaluate the staining patterns of two 
different primary antibodies in the same section. Fluorescent secondary antibodies used 
include DyLight488, Dylight594 (Thermofisher Scientific), and Alexa594 (Invitrogen). 4'6-
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diamidine-2'phenylindole dihydrochloride (DAPI, Sigma-Aldrich), which emits at 461nm 
and shows high binding-affinity to DNA, was used for counterstaining. 
2.6 Urea-based SDS-Page and Western Blot 
The one-dimensional Urea-based SDS Page and Western Blot was employed to evaluate Aβ 
species in the 5xFAD transgenic mouse model of AD. The method allows separation of Aβ 
peptide variants that differ in length by just one amino-acid and was applied as previously 
described (Wiltfang et al. 1997).  
To generate protein extracts, brain tissue from 12-month-old wildtype and 5xFAD mice was 
homogenized in Tris-buffered Saline (TBS. 120 mM NaCl, 50 mM Tris, pH 7.5) in a weight-
to-volume (w/v) ratio of 1:10 with a glass Teflon® homogenizer followed by centrifugation 
for 20 min at 17,000 x g. The supernatant was separated and termed TBS fraction. After 
suspending the resulting pellet in TBS and a second centrifugation the final pellet was 
sonified and dissolved in 2 % sodium dodecyl sulfate (SDS). The lysates were evaluated for 
protein concentrations with the Roti-Quant® protein assay (Carl Roth), a photometric assay 
for protein quantitation according to Bradford. Immunoprecipitation (IP) of Aβ peptides 
from the brain lysates was carried out as previously described (Haussmann et al. 2013; 
Savastano et al. 2015) using magnetic sheep anti-mouse IgG Dynabeads M-280, that were 
precoated overnight with the Anti-Aβ mAb 1E8 (Covance) at 4 °C.   
Samples of a protein concentration of 2 mg/ml were then prepared in electrophoresis buffer 
(0.36 M Bistris, 0.16 M bicine, 15 % (w/v) sucrose, 1 % (w/v) SDS, 0,0075 % bromophenol 
blue) and one-dimensional urea-based SDS-PAGE was applied as previously described 
(Savastano et al. 2015). 10 µl (equivalent to 20 µg of total protein) of each sample were 
separated on a urea Bicine/Bis-Tris/Tris-sulfate SDS-polyacrylamide gel (8 M Urea, 10 % T, 
5 % C, 0.25 % SDS, 0.4 M H2SO4). A standard of synthetic Aβ peptides (Aβ1-37, Aβ1-38, 
Aβ1-39, Aβ1-40, Aβ1-42) was applied, which served as a reference for the electrophoretic 
mobility of the different Aβ variants. Western blot onto a PVDF membrane was performed 
thereafter for 45 min at 1 mA/cm2 using a discontinuous buffer system. The blot was 
assembled from the anode to the cathode as follows: 1 filter paper (extra thick blot filter 
paper, Biorad) that was soaked for 15 min in 0.21 M Tris / 30 % methanol, 1 filter paper 
that was soaked for 15 min in 25 mM Tris / 30 % methanol, a PVDF membrane that was 
equilibrated in 25 mM Tris / 30 % methanol, the polyacrylamide gel which was briefly pre-
incubated in 25 mM Tris-borate (pH 9.0, 0.025 % SDS), and two filter papers that were 
soaked in 25 mM Tris-borate (pH 9.0, 0.025 % SDS). After the blotting was completed the 
PVDF membrane was boiled for 3 min in PBS using a microwave oven to facilitate the 
immunodetection (Ida et al. 1996). Prior to application of the primary antibody the 
membrane was blocked with 2 % GE-block in PBS-T (PBS with 0.0075 % Tween-20) 
overnight at 4 °C under constant agitation. Incubation with mAb 1E8 for 1 h at ambient 
temperature was followed by 3 washing steps by 10 min incubation in PBS-T under constant 
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agitation.  A biotinylated anti-mouse IgG antibody (Linaris) was applied for 45 min as 
secondary antibody. After another 3 washing steps with PBS-T, the blot was incubated with 
streptavidin-coupled horseradish peroxidase for 45 min at ambient temperature. Again 3 
washing steps with PBS-T were performed, before the blots were developed using ECL-
prime (GE-Healthcare) for 5 min at ambient temperature and signals were recorded with a 
LiCor® imager.  
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3 Results 
3.1 Antibody specificity, comparative staining 
Specificity of most primary antibodies used in this study has already been demonstrated by 
the respective supplier (table 1). In context of this study the specificity of the anti-Aβ38 pAb 
#218403 against the C-terminus was tested in immunohistochemistry using an 
immunoadsorption protocol. Preincubation of the anti-Aβ38 pAb with 1g of the Aβ peptide 
Aβ4-38 suppressed the staining almost completely, as seen in comparison with staining using 
the untreated antibody (not shown; see figure 1 of publication I).   
Comparative stainings carried out using the polyclonal rabbit anti-Aβ38 antibody #218403 
and the commercially available monoclonal rabbit anti-Aβ38 antibody BA1-13 revealed 
differences in immunoreactivity in both a case of SAD and in the 3xTg mouse model. 
Staining with the polyclonal anti-Aβ38 antibody #218403 resulted in vastly stronger 
immunoreactivity compared to staining with the mAb BA1-13. Spatial distribution of 
immunoreactivity however, was found to be similar (not shown; see suppl. figure 1 of 
publication I).  
3.2 Sporadic Alzheimer’s Disease 
At first the deposition of the C-terminally truncated Aβ peptide Aβ38 was analyzed in a set 
of SAD and non-demented control cases using the anti-Aβ38 pAb #218403. General Aβ 
pathology was assessed by staining with the pan-Aβ mAb 4G8, which allowed for a 
comparison of Aβ38 depositions with the overall plaque pathology and degree of CAA 
present in the cases investigated (table 2). Vascular staining of Aβ38 could be detected, to a 
varying degree, in the majority (8/13) of SAD cases (figure 2 A,B).  In addition, one of the 
analyzed non-demented control cases showed significant vascular depositions of Aβ38, too.  
The study showed that a strong correlation between the severity of CAA and the amount of 
vascular Aβ38 exists in SAD. In contrast, immunoreactivity to extracellular Aβ38 was hardly 
observed and Aβ38 within NPs could only be faintly detected in two of the SAD cases (figure 
2F), even though plaque pathology was significant in all SAD cases and some of the non-
demented control cases.   
To further investigate the deposition of C-terminally truncated Aβ species, additional 
immunohistochemistry studies on SAD and NDC cases were performed using monoclonal 
antibodies against Aβ37 (D2A6H), Aβ38 (326F1) and Aβ39 (D5Y9L). Again, general Aβ 
pathology was assessed by staining with the pan-Aβ antibody 4G8. In addition, staining with 
the mAb G210 allowed comparison of the C-terminally truncated Aβ peptides with Aβ40 
(table 3). Staining with the anti-Aβ38 mAb 326F1 largely reproduced results of the 
3 Results 14 
abovementioned experiments which were carried out using the polyclonal rabbit anti-Aβ38 
antibody #218403.  
Table 2: Data from publication I on depositions of Aβ38 in sporadic AD cases and non-
demented control cases including demographic data and semiquantitative analysis. 4G8 
antibody was used for evaluation of overall plaqueload and degree of cerebral amyloid 
angiopathy. The pAb #218403 was used for evaluation of Aβ38 depositions. Aβ staining 
intensity was rated as follows: - absent staining; (+) scarce staining, + weak staining, ++ 
moderate staining, +++ abundant staining. 
    Aβ Aβ38 















NP CAA NP CAA 
88 F IV AD ++ + - - 
84 F IV AD ++ - - - 
86 M IV AD + ++ - - 
79 F IV AD ++ +++ - + 
88 F IV AD + - - - 
84 F IV AD ++ + - + 
93 M IV AD + +++ - ++ 
92 M IV AD ++ + - + 
92 F IV AD ++ ++ - + 
91 F IV AD ++ ++ - + 
91 M IV AD + +++ (+) ++ 
92 F IV AD + ++ (+) ++ 
91 F IV AD ++ + - - 
        
70 M 0 NDC - - - - 
90 F I NDC + + - + 
88 F I NDC + - - - 
73 M 0 NDC - - - - 
91 M I NDC - - - - 
78 F I NDC (+) - - - 
84 M I NDC - - - - 
78 M I NDC ++ + - - 
82 F I NDC - - - - 
 
As shown above for Aβ38, depositions of the other two C-terminally truncated Aβ peptides 
Aβ37 and Aβ39 were detected in more than half of the SAD brains that were investigated. 
Interestingly none of the investigated NDC cases showed any immunoreactivity to Aβ37 or 
Aβ39. It became evident that all three C-terminally truncated Aβ species are primarily 
deposited within the vasculature in SAD and that the extent of depositions corresponded 
well to the overall level of CAA, the latter being assessed by 4G8 staining. Although in some 
cases meningeal vessels showed a more pronounced immunoreactivity than parenchymal 
vessels, depositions of C-terminally truncated Aβ peptides were found to be present in both 
leptomeningeal and parenchymal vessels in the majority of the affected SAD cases (figure 
2A-D). Unlike Aβ40, the major Aβ species found in vascular amyloid, the shorter Aβ species 
Aβ37, Aβ38, and Aβ39 were hardly detected within NPs (figure 2E-G). 
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Figure 2: Immunohistochemical staining of SAD cases with antibodies against C-terminally 
truncated Aβ peptides and with anti-Aβ40 mAb G210. Staining of SAD cases using the anti-
Aβ38 pAb revealed prominent immunoreactivity to Abeta38 in vascular compartments in 
the majority of the analyzed cases. Both parenchymal and leptomeningeal vessels were found 
to be affected (A,B). The same holds true for depositions of Aβ37 (C) and Aβ39 (D). Unlike 
the C-terminally truncated Aβ peptides, Aβ40 was found to be deposited within the 
vasculature and the parenchyma in most SAD cases (E). In contrast, parenchymal 
depositions of Aβ38 (F) and Aβ37 (G) were only detected infrequently and Aβ39 was not 
detected within NPs of SAD patients. Scale bars: A,C,D: 100 µm; B,E: 200 µm; F,G: 50 µm. 
Double-immunofluorescence staining was carried out to evaluate co-localization of the 
vascular depositions of C-terminally truncated Aβ peptides with Aβ40.  Aβ37 and Aβ38 were 
found to show either a partial or a complete co-localization with Aβ40 in the vessels of SAD 
patients. Aβ39 on the other hand, was found to show a different staining pattern from Aβ40 
within most vessels (figure 3). Interestingly, prominent immunoreactivity to Aβ40 was seen 
in many vessels that did not show immunoreactivity to Aβ37, Aβ38, and Aβ39 respectively. 
This finding confirms that relevant cross-reactivity of the antibodies against the c-terminally 
truncated Aβ peptides with Aβ40 is unlikely (figure 3A-C). Due to the species of origin of 
the used antibodies, co-localization of the C-terminally truncated Aβ peptides could only be 
tested for Aβ38 and Aβ37 and for Aβ38 and Aβ39 but not for Aβ37 and Aβ39. Aβ38 was 
found to show either a partial or a complete overlap with Aβ37 and Aβ39 respectively (not 
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Table 3: Data from publication II with demographic data and semiquantitative analysis of 
staining intensity of the depositions of Aβ37, Aβ38, Aβ39, and Aβ40 in sporadic AD cases, 
Down Syndrome cases, and non-demented control cases. 4G8 antibody was used for the 
evaluation of overall plaqueload and degree of cerebral amyloid angiopathy. Names of the 
respective mAbs used for evaluation of depositions of Aβ37, Aβ38, Aβ39 and Aβ40 are set 
in brackets. Aβ staining intensity was rated as follows: - absent staining; (+) scarce staining, 
+ weak staining, ++ moderate staining, +++ abundant staining. 
    Aβ Aβ37 Aβ38 Aβ39 Aβ40 















NP CAA NP CAA NP CAA NP CAA NP CAA 
92 M IV AD ++ + - - - + - + + + 
92 F IV AD + ++ - - - + - - + + 
93 M IV AD + +++ - +++ - ++ - ++ ++ +++ 
91 M IV AD ++ +++ - + - + - - ++ +++ 
84 F IV AD ++ + - + - ++ - ++ + ++ 
91 F IV AD ++ ++ - ++ (+) + - + ++ +++ 
88 F IV AD + + - - - - - - + + 
92 F IV AD ++ ++ - + (+) + - + + ++ 
79 F IV AD ++ +++ (+) ++ (+) +++ - ++ ++ +++ 
84 F IV AD ++ - - - - - - - + - 
91 F IV AD ++ + - (+) - - - (+) (+) + 
86 M IV AD + ++ - +++ - ++ - +++ + ++ 
88 F IV AD ++ + - - - - - - - + 
96 F V AD+CAA ++ +++ - + - +++ - ++ ++ +++ 
82 F V AD+CAA ++ +++ - ++ - +++ + +++ +++ +++ 
61 F VI DS ++ - - - - - - - + - 
58 M VI DS ++ ++ (+) + + + - - ++ ++ 
64 F V DS ++ ++ - ++ - ++ - ++ ++ ++ 
91 M I NDC - - - - - - - - - - 
78 F I NDC (+) - - - - - - - - + 
73 M 0 NDC - - - - - - - - - - 
84 M I NDC - - - - - - - - - - 
88 F I NDC + - - - - - - - - - 
78 M I NDC ++ + - - - + - - + ++ 
82 F I NDC - - - - - - - - - - 
70 M 0 NDC - - - - - - - - - - 
 
Two of the analyzed DS cases showed prominent CAA as assessed by 4G8 staining. While 
Aβ38 was detected in both meningeal and parenchymal vessels, Aβ37 and Aβ39 were found 
to be mainly present within meningeal vessels only. Aβ37, Aβ38, and Aβ39 were abundantly 
detected along with Aβ40 within vessels of the two analyzed cases with AD + CAA. 
Surprisingly one of the cases also showed faint immunoreactivity to Aβ39 in extracellular 
plaques (not shown; see suppl. figure 1 of publication II). 
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Figure 3: Double-Immunofluorescence was used to analyze co-localization of the C-
terminally truncated Aβ peptides with Aβ40. Aβ37 (A-C) and Aβ38 (not shown, see figure 
2D-I of publication I) were found to show either a partial or a complete overlap of staining 
patterns with Aβ40 in most affected vessels in SAD. White arrows indicate a vessel clearly 
detected by the anti-Aβ40 mAb G210 (B), while not showing fluorescence after staining by 
the anti-Aβ37 mAb D2A6H (A). Aβ39 was found to show a distinct staining pattern from 
Aβ40 in most vessels (D-F). Images have been published before in publication II (Reinert et 
al. Acta Neuropathologica Communications (2016) 4:24) under the terms of the Creative 
Commons Attribution 4.0 International License. As a modification to the original images 
white arrows have been added here. Scale bars: A-C: 200 µm; D-F: 100 µm 
3.3 Familial Alzheimer’s Disease 
FAD cases with different underlying APP mutations and a case carrying the PSEN1 mutation 
ΔExon 9 were analyzed for depositions of C-terminally truncated Aβ peptides and Aβ40 and 
Aβ42 (table 4). Studies on Aβ38 in FAD included additional cases of FAD carrying mutations 
in PSEN1 (table 4). 
Besides prominent depositions of the C-terminally truncated Aβ peptides in the vasculature, 
some of the FAD cases also exhibited significant immunoreactivity to the peptides in NPs. 
Especially Aβ37 could be detected within NPs, while Aβ38 was less abundant within NPs 
and Aβ39 was confined to the vasculature in most cases. Figure 4 shows a selection of images 
of the stainings that were performed in FAD cases, with special emphasis on Aβ38 (figure 
4B, E-I).  Further images are shown in figure 3 of publication I and figure 2 of publication 
II. 
This study included analyses of a case of the recently described APP mutation I716F 
(Guardia-Laguarta et al. 2010).  Presence of a wide range of Aβ peptides with varying C-
termini was assessed using IHC for the first time. Similar to Aβ40, Aβ37 and Aβ38 (figure 
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4F) were predominantly present within the vasculature, while Aβ42 was found to be mainly 
deposited as NPs. In fact, staining of adjacent brain sections demonstrated that most of the 
NPs only exhibited immunoreactivity to Aβ42, but not to the C-terminally truncated Aβ 
peptides nor to Aβ40. In contrast, NPs of the hippocampal region also showed significant 
immunoreactivity to Aβ37, Aβ38, and Aβ40. Aβ39 depositions on the other hand, were 
barely detected in the studied APP I716F case and were confined to the vasculature.  
 
Table 4: Data from publications I and II including demographic data and semiquantitative 
analysis of the deposition of C-terminally truncated Abeta peptides in cases of FAD. 
Comparison to overall plaquepathology and CAA as assessed by 4G8-staining or to Aβ42 
depositions as assessed by pAb #218703. See table 2 of publication II for further 
information, including evaluation of Aβ40 depositions in FAD cases. *The anti-Aβ38 mAb 
326F1 was used to analyze the case with the APP mutation I716F for Aβ38 depositions, 
while the other cases were analyzed for Aβ38 depositions using the anti-Aβ38 pAb #218403. 
Aβ staining intensity was rated as follows: - absent staining; (+) scarce staining, + weak 
staining, ++ moderate staining, +++ abundant staining. 
    Aβ37 Aβ38* Aβ39 Aβ / Aβ42 














NP CAA NP CAA NP CAA NP CAA 
          Aβ 
64 M APP E693G  ++ ++ + ++ + ++ +++ +++ 
61 F APP KM670/671NL + ++ - ++ - + +++ +++ 
          Aβ42 
47 M APP I716F* ++ ++ + ++ - (+) +++ + 
61 M PSEN1 ΔExon9 ++ ++ + + - + +++ (+) 
69 M PSEN1 ΔExon9 n/a n/a - ++ n/a n/a +++ (+) 
64 M PSEN1 ΔExon9 n/a n/a - + n/a n/a +++ (+) 
          Aβ 
54 M PSEN1 P264L n/a n/a - ++ n/a n/a +++ +++ 
38 M PSEN1 L418F n/a n/a + ++ n/a n/a +++ +++ 
 
The APP mutation KM670/671NL (‘Swedish’), which is caused by a mutation in close 
proximity to the β-secretase cleavage site and is known to increase overall Aβ 
production (Mullan et al. 1992), also exhibited severe CAA with abundant depositions of 
Aβ37, Aβ38, and Aβ39 within the vasculature. Comparison of Aβ37, Aβ38, and Aβ39 
depositions in a case with the APP mutation KM670/671NL (‘Swedish’) showed similar 
spatial distribution of the peptides in most vessels (figure 4A-C). 
Abundant depositions of C-terminally truncated Aβ peptides were found in a case of 
the APP mutation E693G (‘Arctic’). The mutation that increases formation of Aβ oligomers 
most likely through a conformational change of the Aβ peptide  (Nilsberth et al. 2001) led 
to significant depositions of Aβ37, Aβ38, and Aβ39 not only within the vessels but also 
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within NPs. Of all analyzed cases with FAD mutations it was the only case to exhibit Aβ39 
immunoreactivity within NPs.  
In a case of the PSEN1 mutation L418F significant immunoreactivity to Aβ38 was found in 
both the vasculature and amyloid plaques (figure 4H). In contrast analysis of a case of the 
PSEN1 mutation P264F only revealed vascular depositions of Aβ38 (figure 4G).  
This study further included the IHC analysis of three cases of PSEN-1 mutations for 
depositions of Aβ38. While Aβ38 was found in the vasculature in 3/3 analyzed cases of the 
PSEN-1 mutation ΔExon9, immunoreactivity to Aβ38 within amyloid plaques was only 
found in one of the three cases of the mutation (figure 4I). In adjacent sections Aβ38 showed 
an almost completely inverse staining pattern compared to Aβ42 in this case (not shown; see 
figure 3E, F of publication I). Further analysis of this case included staining for Aβ37, Aβ39, 
and Aβ40. While Aβ37, Aβ38, Aβ40, and Aβ42 could be detected to a varying degree within 
NPs in this case, Aβ39 immunoreactivity could only be detected at vascular lesions (not 
shown; see table 2 and figure 2G-I of publication II). 
 
Figure 4: Selection of images showing IHC staining for C-terminally truncated Aβ peptides 
in FAD cases. Vascular depositions of C-terminally truncated Aβ37, Aβ38, and Aβ39 were 
observed in a case with the APP mutation KM670/671NL (‘Swedish’) (A-C). A case of the 
APP mutation E693G (‘Arctic’) showed abundant vascular and parenchymal depositions of 
Aβ as assessed by 4G8-staining (D), while Aβ38 depositions within NPs were less prominent 
(E). Further images show Aβ38 depositions within a case with the APP mutation I716F (F), 
a case with the PSEN1 mutation P264L (G), a case with the PSEN1 mutation L418F (H), 
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and a case with the PSEN 1 mutation ΔExon9 (I). Images A-C have been published before 
in published in publication II (Reinert et al. Acta Neuropathologica Communications (2016) 
4:24) under the terms of the Creative Commons Attribution 4.0 International License. Scale 
bars: A-C: 200 µm; D-I: 100 µm 
 
3.4 Transgenic Mouse Models 
As part of this study a choice of 6 different mouse models of AD with different underlying 
mutations was investigated for depositions of the C-terminally truncated Aβ peptides. The 
results of IHC staining indicate that the C-terminally truncated peptides are generated and 
deposited in common mouse models of the disease (table 5).  
 
Table 5: Data from publication II and publication I. Severity of extracellular Aβ depositions 
was assessed using the anti-Aβ37 mAb D2A6H, the anti-Aβ38 mAB 326F1, the anti-Aβ39 
mAB D5Y9L, the anti-Aβ40 mAb G210. *The APP23 mouse model was analyzed for Aβ38 
using the anti-Aβ38 pAb #218403. For more information on the analyzed mouse models see 
Table 2 of publication I. Aβ staining intensity was rated as follows: - absent staining; (+) 
scarce staining, + weak staining, ++ moderate staining, +++ abundant staining. 
Transgenic model Age Aβ37 Aβ38* Aβ39 Aβ40 
APP/PSEN1ΔExon9 9 m + ++ + +++ 
5xFAD 7 m +++ +++ +++ +++ 
PDAPP 18 m + + + ++ 
APP23* 20 m ++ ++ ++ +++ 
3xTg 18 m ++ ++ ++ +++ 
APP/PSEN1-KI 10 m +++ +++ +++ +++ 
 
In contrast to the staining pattern observed in SAD, immunoreactivity to C-terminally 
truncated Aβ peptides was found predominantly within NPs instead of within vessel walls. 
The investigated mouse models showed a correlation between the amount of 
immunoreactivity to the C-terminally truncated Aβ peptides and immunoreactivity to Aβ40. 
Depositions of C-terminally truncated Aβ peptides were most pronounced in the mouse 
models 5xFAD (figure 5) and APP/PSEN1-KI. Double-IF staining carried out in 7-month-
old 5XFAD mice as well as 10-month-old APP/PSEN1-KI mice showed co-localization of 
Aβ37 and Aβ39 with Aβ40 in extracellular NPs (not shown; see suppl. figure 2 of publication 
II). Similarly, Aβ38 depositions in a 10-month-old APP/PSEN1-KI mouse were found to 
largely overlap with depositions of Aβ40 in the parenchyma, although a small vessel exhibited 
only partial co-localization of the two peptides (not shown; see figure 5K-N of publication 
I). 
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Figure 5: Images of IHC staining of depositions of Aβ37, Aβ38, Aβ39, and Aβ40 in adjacent 
sections at hippocampal region of the brain of a 7-month-old heterozygous 5xFAD mouse. 
Scale bar: 200 µm  
C-terminally truncated Aβ peptides were also detected in lysates of brain tissue of 7-month-
old heterozygous 5xFAD mice. A western blot was performed using anti-Aβ mAb 1E8, 
preceded by immunoprecipitation of Aβ peptides with anti-Aβ mAb 6E10 and a urea-based 
SDS-Page of the lysates. Alongside more distinct bands of Aβ 1-40 and Aβ 1-42, bands of 
Aβ 1-37, Aβ 1-38, and Aβ 1-39 were detected in both the TBS- and SDS-soluble fractions 
of the lysates (figure 6).   
 
 
Figure 6: Western Blot for Aβ peptides in TBS- and SDS-soluble fractions from 7-month-
old heterozygous 5xFAD and wild type (WT) mice. Prior to detection with 1E8 by Western 
Blot, Immunoprecipitation using 6E10 and a Urea-based SDS-Page were performed; 
comparison to a standard of Abeta peptides with varying C-terminus. Figure has been 
published before in publication II (Reinert J, Richard BC, Klafki HW, Friedrich B, Bayer TA, 
Wiltfang J, Kovacs GG, Ingelsson M, Lannfelt L, Paetau A et al. (2016): Deposition of C-
terminally truncated Aβ species Aβ37 and Aβ39 in Alzheimer's disease and transgenic mouse 
models. Acta Neuropathologica Communications 4, 24) under the terms of the Creative 
Commons Attribution 4.0 International License. 
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4 Discussion 
Despite the well-documented C-terminal heterogeneity of Aβ peptides, studies on the 
accumulation of Aβ peptides other than Aβ40 and Aβ42 are rare. The present study, for the 
first time, presents a comprehensive analysis of the depositions of a wide range of C-
terminally truncated peptides in post-mortem tissue of patients affected by sporadic and 
familial AD.  Comparison of Aβ37, Aβ38, and Aβ39 accumulations with overall Aβ 
pathology documents the severity and the predominant location of their depositions.  
Although all of these peptides have been shown to occur in human CSF and blood plasma 
(Maler et al. 2007; Wiltfang et al. 2002; Welge et al. 2009) as well as within aqueous extracts 
of brain tissue (Portelius et al. 2010b), their involvement in the characteristic 
neuropathological changes in AD and in disease pathogenesis has not been thoroughly 
investigated. While absent from NDC cases, the three abovementioned C-terminally 
truncated peptides have been identified in a subset of AD cases and cases of pathologic aging 
in a recent Analysis using mass spectrometry of human brain lysates (Moore et al. 2012). 
C-terminally truncated Aβ peptides have been shown to exhibit lower aggregation properties 
as compared to longer species (Vandersteen et al. 2012) and a high solubility in vitro 
(Schlenzig et al. 2012; Bouter et al. 2013). A study on FAD cases carrying the APP mutation 
D694N (‘Iowa’) found Aβ38 to represent a major fraction of Aβ species within the 
cerebrovascular compartment, while accounting for only a minor fraction of parenchymal 
Aβ (Tomidokoro et al. 2010). From this study, it can be inferred that Aβ38 is generally more 
likely to be found within vascular Aβ depositions rather than within NPs in AD patients. 
Very recently Moro et al. reported results of immunohistochemical analyses of peptide 
depositions in the brains of AD patients that indeed found Aβ38 to be predominantly 
detectable within the vasculature. However, in SAD depositions of Aβ38 were found to be 
confined to a small subset of analyzed cases which exhibited severe CAA (Moro et al. 2012). 
In good agreement with these findings, the study at hand shows Aβ38 to be mainly detectable 
within the vasculature of the SAD cases that were analyzed using the polyclonal rabbit anti-
Aβ38 antibody #218403. In contrast to the aforementioned report by Moro et al., this study 
found Aβ38-immunoreactivity in the majority (8/13) of the analyzed SAD cases which 
harbored a varying degree of CAA. In addition, one of the nine analyzed NDC cases 
exhibited significant Aβ38-immunoreactivity within vessels of the brain. However, 
parenchymal depositions of the peptide were barely observed in SAD, as only two cases 
showed limited immunoreactivity to Aβ38 and only a low number of plaques were stained. 
Notably, the amount of vascular Aβ38 depositions in SAD was found to depend largely on 
the varying degree of CAA of the analyzed cases, as assessed by immunohistochemical 
staining with the anti-Aβ mAb 4G8. All the above was basically reproducible using the 
monoclonal mouse anti-Aβ38 antibody 326F1. This further confirms the results that were 
achieved using the polyclonal rabbit antibody. Minor differences in the results of the analyses 
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can be explained by (i) different section depth of the analyzed tissue or (ii) minor irregularities 
during staining protocol, e.g. insufficient exposure of the slice to the antibody due to 
unnoticed leakage of the applied solution from the slice during overnight incubation.  
Comparative stainings were carried out with the anti-Aβ38 antibody used in the present (pAb 
#218403) and the one used in the previous study (mAb BA1-13) by Moro et al. It is 
conceivable that the observed differences in sensitivity of the antibodies account for the 
detection of Aβ38 in more cases of SAD in the present study as compared to the previous 
study. 
As the present study was extended to include analyses of Aβ37 and Aβ39, it became evident 
that the vascular Aβ depositions in SAD contain a broad spectrum of C-terminally truncated 
Aβ peptides. Considering the fact that the severity of depositions of Aβ37 and Aβ39 in SAD 
was again found to correlate well with the degree of CAA in the analyzed cases, it can be 
concluded that the two peptides generally share a similar pattern of depositions with Aβ38. 
This was further confirmed by double-IF staining for Aβ37 and Aβ38 and for Aβ39 and 
Aβ38, which showed either partial or complete overlap of the vascular depositions in a case 
of SAD. 
While Aβ37, Aβ38, and Aβ39 have essentially been confined to the vasculature in SAD, some 
of the analyzed FAD cases have been found to exhibit depositions of the peptides in the 
parenchyma as well. To allow insights into the mechanism involved in the generation of each 
C-terminally truncated Aβ peptide different APP mutations were chosen, located at the C-
terminal part of Aβ (APP mutation I716F), at the N-terminal part of Aβ (APP mutation 
KM670/671NL ‘Swedish’) and within the Aβ-coding region (APP mutation E693G ‘Arctic’) 
(figure 1). This study further comprises analyses of PSEN1 mutations that have been shown 
to enhance accumulation by changing the spectrum of Aβ-peptides produced, thereby 
increasing the Aβ42:Aβ40 ratio. (Czech et al. 2000) 
Based on observations made in FAD cases, it was hypothesized that Aβ38 depositions were 
specifically associated with those APP mutations that are found inside the Aβ-coding region 
of the APP gene, while APP mutations located adjacent to the Aβ-coding region did not 
favor accumulation of the peptide. In addition, several cases with underlying mutations in 
the presenilin genes were reported to lack Aβ38 depositions (Moro et al. 2012). 
Although the present study confirms the occurrence of abundant vascular and parenchymal 
depositions of Aβ38 in a case with the APP mutation E693G (‘Arctic’), it also found 
considerable accumulations of the peptide within the brains of patients with underlying APP 
mutations that are located outside of the Aβ coding region. These include a case of the APP 
mutation KM670/671NL (‘Swedish’), which is located directly adjacent to the Aβ coding 
region of APP at the β-secretase cleavage site, and a case of the APP mutation I716F, which 
is located in proximity to the C-terminal sequence of Aβ. The case mentioned first exhibits 
prominent vascular depositions of the C-terminally truncated Aβ peptides including Aβ38, 
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the case with the underlying APP mutation I716F shows both vascular and parenchymal 
depositions of Aβ38.   
Moreover, the present study shows Aβ38 to occur as both parenchymal and vascular 
depositions in patients with underlying mutations in the PSEN1 gene. While Aβ38 within 
NPs was only found in one patient carrying the PSEN1 mutation ΔExon9 and one patient 
carrying the PSEN1 mutation L418F, vascular Aβ38 depositions have been observed in all 
analyzed FAD cases with PSEN1 mutations. However, none of the PSEN1 mutations that 
have been analyzed here had previously been assessed for Aβ38 pathology and it is important 
to point out that it has been demonstrated that the generation of Aβ38 and Aβ42 can be 
differentially affected by different FAD causing PSEN mutation (Page et al. 2008). 
Therefore, the detection of Aβ38 depositions in the analyzed cases does not necessarily argue 
against the previous study which found no Aβ38 depositions in cases of FAD with other 
underlying PSEN1 mutations (Moro et al. 2012). 
In conclusion though, the results of this study reject the assumption that Aβ38 might be 
limited to cases with underlying the intra-Aβ APP mutation in FAD and imply that Aβ38 
depositions within the vasculature are commonly found in FAD and SAD.   
Early studies on cerebrovascular Aβ already proposed that vascular Aβ, while homologous 
to plaque core Aβ, consists of shorter peptides made up of only 39 rather than 42 amino 
acids (Prelli et al. 1988). Later Aβ40 was shown to be the predominant species within cerebral 
vessels, while Aβ39 was found to account for a smaller fraction of vascular Aβ (Miller et al. 
1993). Confirming these early results, the present study has found that depositions of Aβ39 
are essentially limited to the vasculature. While Aβ37 and Aβ38 were also found in NPs of 
various analyzed FAD cases, parenchymal Aβ39 depositions were confined to one case 
carrying the intra-Aβ APP mutation E693G (‘Arctic’). This mutation has been described to 
enhance aggregation propensities and hinder proteolytic degradation of Aβ (Nilsberth et al. 
2001; Tsubuki et al. 2003). Intra-Aβ APP mutations in general have been described to present 
a distinct neuropathology that is characterized by severe CAA in most cases (Nilsberth et al. 
2001). In line with this, the present study documents severe CAA in a case of the APP 
mutation E693G (‘Arctic’) and reveals great C-terminal heterogeneity of the deposited β-
amyloids within both the vasculature and NPs.  
While detection of numerous NPs by immunostaining for Aβ and by Bielschowsky silver 
staining has been reported for a case of the APP mutation I716F recently, characterization 
of Aβ deposition with respect to the C-terminus had not been carried out before 
(Sieczkowski et al. 2014). The present study has found abundant accumulations of Aβ 
peptides in a case of the APP mutation I716F, with Aβ42 representing the main species 
within NPs. This is in line with earlier studies that predicted the APP mutation I716F to 
cause extraordinary severe Aβ accumulation based on in vitro experiments (Lichtenthaler et 
al. 1999). There is profound evidence that the mutation causes immensely increased Aβ42 
production mainly by a drastic change in Aβ42:Aβ40 ratio (Herl et al. 2009). This has been 
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interpreted to be a result of impaired γ-secretase cleavage, which purportedly leads to a shift 
in classic Aβ product lines. Hence the mutation has been proclaimed to favor the product 
line that includes production of Aβ42 (Aβ48 > Aβ45 > Aβ42 > Aβ38) over the product line 
leading primarily to production of Aβ40 (Aβ49 > Aβ46 > Aβ43 > Aβ40) (Suárez-Calvet et 
al. 2014). The present study shows significant Aβ38 depositions within vessels and 
parenchyma of the analyzed case, which can be explained with the common product line of 
Aβ42 and Aβ38. Yet the relatively scarce depositions of Aβ39 and the abundant depositions 
of Aβ37 – a species which has been found to primarily result from the release of GVV 
tripeptide from Aβ40 – might underscore recent findings about deviations from the major 
product lines of γ-secretase (Matsumura et al. 2014).  
Surprisingly, Aβ37 was detected in NPs of all analyzed FAD cases with underlying APP 
mutation, and depositions were found to be more prominent than depositions of the other 
two analyzed C-terminally truncated Aβ peptides. This raises further questions about 
differences in properties of the three peptides and their ways of generation in FAD. Multiple 
pathways of successive γ-secretase cleavages have been described to lead to the formation of 
C-terminally truncated Aβ peptides. This includes the release of the GVVIA pentapeptide 
from Aβ42 that leads to the release of Aβ37 (Matsumura et al. 2014). It is possible that this 
γ-secretase action is responsible for the relative abundance of Aβ37 depositions in APP 
mutation carriers that exhibit high levels of Aβ42.  
Although the C-terminally truncated Aβ peptides and Aβ40 exhibit similar aggregation 
propensities in vitro (Vandersteen et al. 2012), this study has found depositions of the C-
terminally truncated Aβ peptides to be significantly less abundant in SAD than depositions 
of Aβ40.  Undoubtedly part of this can be explained by the lower production rates of the C-
terminally truncated peptides. It is interesting that depositions of the C-terminally truncated 
Aβ peptides within plaques were found to be almost confined to FAD cases. This could be 
explained by the generally more severe neuropathology that was documented for the 
analyzed cases in this study. Although this would need to be confirmed in additional studies 
it seems likely that the deposition of C-terminally truncated Aβ peptides to NPs represents 
a late event in the development of AD neuropathology. 
While APP processing has been shown to primarily result in the formation of Aβ40, the C-
terminally truncated Aβ peptides Aβ37, Aβ38, and Aβ39 have been found to be produced at 
lower rates comparable to that of Aβ42 (Younkin 1998; Suzuki et al. 1994; Beher et al. 2002). 
Subtle changes of production rates have been found to heavily influence the aggregation 
process of the resulting Aβ mixture. It has been proposed that the relative production rather 
than the absolute amount of toxic Aβ peptides is crucial for the aggregation of Aβ in vivo. 
In this regard the Aβ42:Aβ40 production ratio seems to be of particular importance 
(Kuperstein et al. 2010).  Interestingly, Aβ40 has been found to hinder the aggregation of 
Aβ42 both in vitro and in mouse models of AD (Portelius et al. 2010b). On these grounds 
speculation about a putative protective role of Aβ40 has emerged (Kim et al. 2007; Jan et al. 
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2008), which has recently received further support by a study on the effect of different Aβ 
peptides on tau phosphorylation (Hu et al. 2014). A similar protective function of C-
terminally truncated Aβ species has been put up for debate after findings of a massive 
decrease of Aβ37, Aβ38, and Aβ39 in the CSF of FAD cases (Portelius et al. 2010a).   
In SAD the concentrations of the C-terminally truncated Aβ peptides within the CSF have 
been shown to increase in a disease-specific manner and a possible role as biomarkers for 
incipient AD has been proposed (Wiltfang et al. 2002). In this regard, subsequent research 
on CSF of SAD patients has rendered Aβ38 to be the most suitable among the C-terminally 
truncated Aβ peptides. Determination of the peptide’s CSF concentration has been found to 
increase diagnostic specificity of CSF analysis if combined with measurements of tau, Aβ40, 
and Aβ42 (Welge et al. 2009). Certainly, the mechanisms behind the characteristic changes 
in CSF and the concomitant deposition of the Aβ peptides within the brain in SAD patients 
that have been observed in the present study are intertwined. This is underlined by the fact 
that depositions of C-terminally truncated Aβ peptides, while present in the majority of 
analyzed SAD cases, have hardly been detected in NDC cases. 
This study has also found the C-terminally truncated Aβ species to be deposited within NPs 
in the brains of a set of widely used mouse models of AD. The presence of such peptides in 
transgenic lines had not been demonstrated before. Aβ 37, Aβ38, and Aβ39 have been found 
to be deposited to NPs in all analyzed mouse models; the severity of their depositions has 
been found to depend on the overall severity of plaque pathology exhibited by each analyzed 
mouse model. In contrast, vascular depositions have been found to be absent in most 
models, which is best explained by the fact that most models generally exhibit hardly any 
vascular Aβ depositions. Western Blot analysis of 5XFAD mice has revealed significantly 
less Aβ1-37, Aβ1-38, and Aβ1-39 compared to Aβ1-40 and Aβ1-42. However, their presence 
in mouse models might represent a potential read-out to assess efficacy of GSMs in vivo. 
For this purpose, a ratio of plaques with immunoreactivity to Aβ42 and plaques with 
immunoreactivity to Aβ37/38/39 after Immunohistochemical staining could be established. 
Alternatively, biochemical methods such as Mass spectrometry or ELISA could be employed 
to directly measure levels of the C-terminally truncated Aβ peptides. 
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Taken together, the study at hand provides evidence for the presence of a broad range of C-
terminally modified Aβ peptides in SAD and FAD patients. In good agreement with earlier 
research on the solubility of the peptides, the predominant location of depositions of Aβ37, 
Aβ38, and Aβ39 has been found to be the vasculature. In SAD cases a clear correlation 
between severity of CAA and amount of accumulations of the peptides could be established. 
Parenchymal depositions have been found in some of the analyzed FAD cases. Interestingly, 
the underlying mutations have affected the accumulation of Aβ37, Aβ38, and Aβ39 
differently. It is noteworthy that FAD mutations were generally found to cause significant 
vascular depositions of the C-terminally truncated Aβ peptides that were investigated in this 
study. As observed in the FAD cases, the Aβ depositions within NPs in brains of transgenic 
mouse models that are based on FAD causing mutations have been found to exhibit great 
C-terminal heterogeneity as well. 
Additional studies are needed to further elucidate the exact role of C-terminally truncated 
Aβ peptides in AD pathogenesis including possible protective functions, effects of new AD 
treatments on their production, and the cause for the observed C-terminal heterogeneity in 
Aβ depositions. 
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6.1 Copyright statement 
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